Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.peptides.2021.170583 http://scihub22266oqcxt.onion/10.1016/j.peptides.2021.170583 34087220!8168367!34087220     free     free     free       Peptides 2021 ; 143 (ä): 170583 Nephropedia Template TP {{tp|p=34087220|t=2021. Synthetic proteins for COVID-19 diagnostics |pdf=|usr=}}{{34087220}} gab.com Text Synthetic proteins for COVID-19 diagnostics JO: Peptides http://www.kidney.de/pget.php?&tw=1&pmid=34087220 #FOAvip There is an urgent need for inexpensive, rapid and specific antigen-based assays to test for vaccine efficacy and detect infection with SARS-CoV-2 and its variants. We have identified a small, synthetic protein (JS7), representing a region of maximum variability within the receptor binding domain (RBD), which binds antibodies in sera from nine patients with PCR-verified COVID-19 of varying severity. Antibodies binding to either JS7 or the SARS-CoV-2 recombinant RBD, as well as those that disrupt binding between a fragment of the ACE2 receptor and the RBD, are proportional to disease severity and clinical outcome. Binding to JS7 was inhibited by linear peptides from the RBD interface with ACE2. Variants of JS7, such as E484K or N501Y, can be quickly synthesized in pure form in large quantities by automated methods. JS7 and related synthetic antigens can provide a basis for specific diagnostics for SARS-CoV-2 infections. Twit Text FOAVip Synthetic proteins for COVID-19 diagnostics ????Peptides http://www.kidney.de/pget.php?&tw=1&pmid=34087220 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34087220 #FOAvip English Wikipedia <ref>{{Cite pmid|34087220}}</ref> Synthetic proteins for COVID-19 diagnostics #MMPMID34087220 Schein CH; Levine CB; McLellan SLF; Negi SS; Braun W; Dreskin SC; Anaya ES; Schmidt J Peptides 2021[Sep]; 143 (ä): 170583 PMID34087220show ga There is an urgent need for inexpensive, rapid and specific antigen-based assays to test for vaccine efficacy and detect infection with SARS-CoV-2 and its variants. We have identified a small, synthetic protein (JS7), representing a region of maximum variability within the receptor binding domain (RBD), which binds antibodies in sera from nine patients with PCR-verified COVID-19 of varying severity. Antibodies binding to either JS7 or the SARS-CoV-2 recombinant RBD, as well as those that disrupt binding between a fragment of the ACE2 receptor and the RBD, are proportional to disease severity and clinical outcome. Binding to JS7 was inhibited by linear peptides from the RBD interface with ACE2. Variants of JS7, such as E484K or N501Y, can be quickly synthesized in pure form in large quantities by automated methods. JS7 and related synthetic antigens can provide a basis for specific diagnostics for SARS-CoV-2 infections. |*COVID-19[MESH] |*COVID-19 Serological Testing[MESH] |*SARS-CoV-2[MESH] |Angiotensin-Converting Enzyme 2/chemistry[MESH] |Humans[MESH] |Peptides/*chemistry[MESH] |Protein Domains[MESH]Synthetic proteins for COVID-19 diagnostics (epmc).pdf DeepDyve Pubget Overpricing